Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Galectin-3 in vitro diagnostic assay (BG Medicine Inc.) for the management of patients with chronic heart failure. Lansdale: HAYES, Inc.. Health Technology Brief Publication. 2013 Authors' conclusions There are 5 to 6 million people in the United States with heart failure (HF); the risk of its development is 1 in 5 for both men and women. Serum biomarkers can be a convenient way to assess HF prognosis and response, including galectin-3, a protein derived from cardiac tissue. Currently, B-type natriuretic peptide (BNP) and amino-terminal proB-type natriuretic peptide NTproBNP are used to determine prognostic categories for patients with HF. These 2 blood tests are recommended by the American College of Cardiology Foundation and the American Heart Association for patients with dyspnea in whom the contribution of HF is unknown. However, BNP and NTproBNP are influenced by age, renal function, and anemia. An emerging marker of ventricular remodeling and fibrosis is the serum protein galectin-3. Indexing Status Subject indexing assigned by CRD MeSH Enzyme-Linked Immunosorbent Assay; Galectin 3; Heart Failures Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo@hayesinc.com AccessionNumber 32014000390 Date abstract record published 20/02/2014 |